Found: 9
Select item for more details and to access through your institution.
Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment.
- Published in:
- Clinical Drug Investigation, 2018, v. 38, n. 11, p. 1041, doi. 10.1007/s40261-018-0695-4
- By:
- Publication type:
- Article
Oral SSTR5 Antagonist SCO‐240 for Growth Hormone Stimulation: A Phase I Single‐Dose Study in Healthy Individuals.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1326, doi. 10.1002/cpt.3212
- By:
- Publication type:
- Article
A Randomized, Single‐Center, Double‐Blind, Placebo‐Controlled Multiple‐Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 11, p. 1516, doi. 10.1002/jcph.1142
- By:
- Publication type:
- Article
Increases of microRNA let-7e in peripheral blood mononuclear cells in Hashimoto's disease.
- Published in:
- Endocrine Journal, 2016, v. 63, n. 4, p. 375, doi. 10.1507/endocrj.ej15-0577
- By:
- Publication type:
- Article
Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects.
- Published in:
- Basic & Clinical Pharmacology & Toxicology, 2018, v. 123, n. 5, p. 607, doi. 10.1111/bcpt.13050
- By:
- Publication type:
- Article
Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study.
- Published in:
- Cardiovascular Therapeutics, 2015, v. 33, n. 6, p. 317, doi. 10.1111/1755-5922.12146
- By:
- Publication type:
- Article
Erratum. SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans. Diabetes 2021;70:2364–2376.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans.
- Published in:
- 2021
- By:
- Publication type:
- journal article
751-P: First-in-Human, Single and Repeated Dose Study of SCO-267, a GPR40 Full Agonist, in Healthy Adults and Subjects with Glucose Intolerance.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-751-P
- By:
- Publication type:
- Article